In what emerged as a much controversial and hyped statement, Chief Medical Officer of the American Cancer Society, Dr. Otis Brawley, revealed that breast and prostate cancer screening has its set of definite limitations.
A huge storm of controversy was whipped up as a result of Brawley's statement which hinted that advantages of screening in the cases of the aforementioned two cancers are sometimes overplayed.
While health experts have been warning people of the possible inaccuracy and dangers of screening in the cases of breast and prostate cancers for many years now, Brawley's statement caught much fire and fueled people's suspicions. Screening tests, according to some health experts, more often than not, give out false positives, a belief backed by Brawley's recent statement.
Many believe that the statement should not have caused such hype, as the dangers and inaccuracies of screening tests have been revealed and discussed for long. Also, experts believe that patients need to understand that in cases of breast and prostate cancer, screening itself can come as a risk. Patients, they say, need to find out more about these screening tests and risks involved with them.
Related News
- Cancer Society Caught Up in Controversy; Overplayed Breast, Prostate Cancer Screening Benefits
- New recommendations for prostate screening
- Caution urged in prostate test
- Some Breast Cancer Surgeries 'Unnecessary', Screening to be Blamed - Research
- New Breast Cancer Screening Guidelines Spark Health Bill Debate
- Prostate Cancer Patients to be Tested Before Treatment, Claims Researchers
- Watch-and-Wait Approach to Prostate Cancer Might be Better than Surgery - Study
Good News USA
Entertainment News
- Universal Music Looking to "Bring New Life" to Flagging Format by Pulling Down CD Costs
- Icahn Offers to Buy all of Lions Gate’s Shares For $6 each
- CEO EK of Spotify Looking to Offer Music Streaming Services to the States
- Shares Go Bust Over Blockbuster Bankruptcy Concerns
- Music blogging network MOG raises $9.5 million in new funding round
